Inflexion backs pet supplements maker Lintbells

A spokesperson for Inflexion confirmed Enterprise Fund IV, which closed in May 2016 on £250m, was the vehicle used for the transaction. Management has retained a stake, unquote" understands. 

Inflexion backs both majority and minority investments, typically investing £10-150m of equity in each deal. 

The GP has made previous investments in the petcare market. It acquired a minority stake in UK veterinary clinics operator Medivet last February, and in November 2015, Inflexion carved out Kynetec, a provider of market data to companies operating in the pet sector. Kynetec secured a refinancing from Lloyds Bank Commercial Banking in July 2017.

The backing of Inflexion will allow Lintbells to acquire new customers, launch new products and expand internationally. 

Company
Founded in 2006 and based in Weston, Lintbells researches, formulates and manufactures natural supplements that aim to improve the lives of dogs, cats and horses. A source close to the deal mentioned the company generated a turnover of £10m in 2016 and was expected to have a 30% growth in 2017.

Lintbells exports products to several European and Asian markets. The company employs 62 staff. 

People
Inflexion Private Equity – Tim Smallbone (partner); Ben Long (investment director); Robin Senivassen (investment executive).
Lintbells – John Howie (CEO, co-founder).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Consumer
• Inflexion Private Equity